914289-34-2

Upstream product

• 36526-32-6 ethyl 3-amino[2,3-b]pyrazine-2-carboxylate 
• 773140-42-4 2-bromo-5-fluorobenzoyl chloride 
• 914289-37-5 4-[[2-(5-bromo-2-fluorophenyl)pteridin-4-yl]amino]nicotinic acid methyl ester 
• 936565-01-4 3-[bis-(5-bromo-2-fluoro-benzoyl)-amino]-pyrazine-2-carboxylic acid ethyl ester 
• 914289-32-0 3-(5-bromo-2-fluorobenzoylamino)pyrazine-2-carboxamide 
• 914289-36-4 2-(5-bromo-2-fluorophenyl)-4-chloropteridine 

Relevant academic research and scientific papers

Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors

Screening of a focused library of TGF beta kinase inhibitors in the cellular HCV replicon model with luciferase read out yielded a number of low micromolar HCV inhibitors. Medicinal chemistry driven optimization resulted in the discovery of 4-[2-(5-bromo-

PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF

The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their u